Once considered a nuclear homebody, TDP-43 ventures out to accompany mRNAs down axons to nerve terminals where the transcripts can be turned into protein.
Government, industry, and advocacy together will provide nearly $130 million for the identification of surrogate markers and targets.
It’s not just for tugging APP around the neuron: The SORLA receptor may also bind Aβ and hasten its demise.
Mutant FUS meddles with RNA splicing and DNA damage repair in transgenic mice that succumb to disease.
The antidepressant citalopram reduces agitation in Alzheimer’s patients, but caused abnormal heart rhythms at the tested dose.
Researchers have identified the striatum as a site of neurogenesis in the adult brain, but not in people with Huntington’s disease.
New research suggests that α-synuclein comes in multiple strains, one of which seeds aggregation of tau.
AD but no Amyloidβ? Researchers at AAIC 2013 theorized on the pathology underlying this form of dementia.
In neurodegenerative disease, tau is in the dendrites, and scientists are beginning to flesh out ways to block what it does there.
New research strengthens the idea that microglia do far more than scour the brain for emergencies.
Researchers have co-opted a molecular transport system to shuttle Aβ antibodies across the mouse blood-brain barrier. They predict the shuttle could smuggle a variety of drugs into the brain.
A small study suggests that exposure to the pesticide DDT heightens the risk of developing Alzheimer’s disease.
A transcription factor thought to mark stressed-out motor neurons activates genes that help them survive. It maintains muscle mass, but not strength.
New strategies may help find and retain participants for Alzheimer’s trials.
Researchers report that they can visualize the "glymphatic pathway" in rat brains by using contrast-enhanced magnetic resonance imaging...